Free Trial
OTCMKTS:MCUJF

Medicure 4/25/2025 Earnings Report

Medicure logo
$0.81 0.00 (0.00%)
As of 07/16/2025

Medicure EPS Results

Actual EPS
-$0.04
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Medicure Revenue Results

Actual Revenue
$4.21 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Medicure Announcement Details

Quarter
Time
After Market Closes
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

Medicure's next earnings date is estimated for Tuesday, August 12, 2025, based on past reporting schedules.

Conference Call Resources

Medicure Earnings Headlines

Forget Nvidia, This “Ghost Town” Company Holds the Key to the AI Boom
Cold War Discovery Could Unlock $100 Trillion in Wealth Jeff recently traveled to an American ghost town to investigate this crazy Cold War story… Because it could hold the key to the entire $100 trillion AI boom. It involves an American ghost town with just 30 people… And a new twist to the AI boom that could make a lot of people rich.
Medicure Inc. (MCUJF) Q4 2024 Earnings Call Transcript
See More Medicure Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Medicure? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Medicure and other key companies, straight to your email.

About Medicure

Medicure (OTCMKTS:MCUJF) is a Canadian specialty pharmaceutical company headquartered in Montreal, Quebec. The company focuses on the development, manufacture and commercialization of branded hospital and ambulatory care products, with a primary emphasis on therapies that support cardiovascular care. Medicure’s product portfolio includes prescription injectables and oral therapies designed to address acute care needs such as arrhythmia management, supportive care in surgical settings and hospital-based symptomatic relief.

In addition to its marketed products, Medicure maintains a pipeline of investigational assets targeting cardiovascular and perioperative complications. The company employs a hybrid model of in-house research and strategic partnerships to advance clinical candidates through regulatory pathways. Through these collaborations, Medicure seeks to bolster its core offerings and extend its reach into adjacent specialty therapeutic areas.

Founded in 2005 under the name Cardiome Pharmaceuticals, the company rebranded as Medicure in 2015 to reflect its broader focus on acute care treatment solutions. Over the years, Medicure has grown through a combination of internal development, licensing agreements and targeted acquisitions. These strategic moves have enabled the firm to expand its presence across North America and lay the groundwork for international distribution.

Under the leadership of Chief Executive Officer Angelo Jacovides and an experienced management team, Medicure has built a dedicated sales organization and forged key distribution partnerships. The company primarily serves hospitals, clinics and specialty pharmacies in Canada and the United States, leveraging contract manufacturing relationships and a network of commercial partners to ensure consistent supply and market access for its products.

View Medicure Profile

More Earnings Resources from MarketBeat